Hospital
Orrville Hospital Foundation
Orrville Hospital Foundation was paid $4.35M by Medicaid between Jan 2018 and Dec 2024, across 161 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoORRVILLE HOSPITAL FOUNDATION
ORRVILLE, OH 44667
ORRVILLE, OH 44667
33aNPI1891718375assigned 07/25/2006
33bProvider typeCritical Access Hospital
28Total paid$4.35M
24GClaims125,654
24DCodes billed161
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#17 of 26
Median peer was paid$5.33M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LUNTZ, ADAM controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,910 | $212K | |
| 2019 | 2,266 | $154K | |
| 2020 | 1,463 | $127K | |
| 2021 | 2,848 | $158K | |
| 2022 | 4,335 | $224K | |
| 2023 | 64,051 | $1.95M | |
| 2024incomplete | 47,781 | $1.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 7,846 | 7,044 | $973K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10% | 4,038 | 3,609 | $447K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 2,795 | 2,254 | $411K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 798 | 602 | $242K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 775 | 580 | $216K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 1,283 | 974 | $191K |
| 80053 | Comprehensive metabolic panel | 3.5% | 7,236 | 6,087 | $151K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 1,303 | 388 | $123K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.6% | 2,310 | 2,000 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 571 | 377 | $106K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.1% | 4,072 | 3,680 | $93K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 272 | 180 | $85K |
149 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.7% | 545 | $72K |
| 87631 | 1.6% | 472 | $71K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.6% | 474 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 10,000 | $66K |
| 80061 | Lipid panel | 1.4% | 4,103 | $61K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 2,170 | $57K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 447 | $56K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 415 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,550 | $38K |
| 84439 | <1% | 1,446 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 360 | $33K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,362 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 162 | $28K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 425 | $27K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 562 | $25K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 71 | $23K |
| 82607 | <1% | 845 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,666 | $20K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 355 | $19K |
| G0378 | Hospital observation service, per hour | <1% | 253 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,069 | $18K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 721 | $15K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 50 | $14K |
| 76801 | <1% | 119 | $14K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 93 | $13K |
| 86803 | <1% | 509 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 541 | $12K |
| 82570 | <1% | 978 | $12K | |
| 82728 | <1% | 684 | $11K | |
| 86592 | <1% | 357 | $11K | |
| 83540 | <1% | 887 | $11K | |
| 83880 | <1% | 760 | $9K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 33 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 266 | $9K |
| 84153 | <1% | 457 | $8K | |
| 86850 | <1% | 291 | $8K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 167 | $7K |
| 86038 | <1% | 228 | $7K | |
| J3490 | Unclassified drugs | <1% | 612 | $7K |
| 83735 | <1% | 1,201 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,135 | $7K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 304 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 98 | $7K |
| 84481 | <1% | 437 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 151 | $6K |
| 87077 | <1% | 524 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 311 | $6K |
| 82043 | <1% | 743 | $6K | |
| 87070 | <1% | 316 | $5K | |
| 86900 | <1% | 353 | $5K | |
| 0011A | <1% | 144 | $4K | |
| 0012A | <1% | 121 | $4K | |
| 83550 | <1% | 426 | $4K | |
| 87390 | <1% | 160 | $4K | |
| 86703 | <1% | 175 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 325 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,907 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,385 | $3K |
| 85652 | <1% | 469 | $3K | |
| 86140 | <1% | 385 | $3K | |
| 83970 | <1% | 108 | $3K | |
| 73630 | <1% | 207 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 94 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 184 | $3K |
| 86901 | <1% | 338 | $2K | |
| 87480 | <1% | 169 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,142 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,181 | $2K |
| 82746 | <1% | 205 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 345 | $2K |
| 85610 | <1% | 599 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,623 | $2K |
| 81001 | <1% | 1,675 | $2K | |
| 84484 | <1% | 1,249 | $2K | |
| 83690 | <1% | 1,222 | $2K | |
| 76642 | <1% | 15 | $2K | |
| 93017 | <1% | 20 | $2K | |
| 87660 | <1% | 169 | $2K | |
| 73562 | <1% | 64 | $2K | |
| 80320 | <1% | 108 | $2K | |
| 99201 | <1% | 12 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 151 | $2K |
| 84403 | <1% | 80 | $2K | |
| 81003 | <1% | 1,165 | $2K | |
| 86431 | <1% | 77 | $1K | |
| 87186 | <1% | 282 | $1K | |
| 87510 | <1% | 169 | $1K | |
| 84702 | <1% | 82 | $1K | |
| 84550 | <1% | 171 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 134 | $1K |
| 80076 | <1% | 43 | $886.90 | |
| 73610 | <1% | 120 | $858.80 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,476 | $840.70 |
| 96376 | <1% | 164 | $776.40 | |
| 85007 | <1% | 115 | $704.16 | |
| 97162 | <1% | 15 | $587.60 | |
| 85379 | <1% | 204 | $556.74 | |
| 73030 | <1% | 15 | $499.26 | |
| 81025 | <1% | 1,393 | $488.11 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 89 | $480.93 |
| 73130 | <1% | 34 | $423.94 | |
| 84156 | <1% | 79 | $410.24 | |
| 82947 | <1% | 28 | $409.66 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 955 | $381.70 |
| 86618 | <1% | 12 | $221.64 | |
| 87040 | <1% | 141 | $203.82 | |
| 83605 | <1% | 134 | $203.20 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $186.67 |
| 80305 | <1% | 103 | $148.52 | |
| 73110 | <1% | 14 | $108.97 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 421 | $101.73 |
| 90715 | <1% | 13 | $99.19 | |
| 82962 | <1% | 289 | $99.08 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 344 | $94.48 |
| 85730 | <1% | 30 | $85.72 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,180 | $84.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 647 | $57.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,858 | $54.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 186 | $29.74 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 29 | $26.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 67 | $23.61 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 592 | $22.79 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $17.97 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 97 | $17.71 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 493 | $13.17 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 260 | $13.14 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 412 | $3.05 |
| 91301 | <1% | 244 | $2.34 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 84 | $1.04 |
| 1159F | 0% | 199 | $0.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 119 | $0.00 |
| 3288F | 0% | 95 | $0.00 | |
| 3078F | 0% | 522 | $0.00 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 54 | $0.00 |
| 00731 | 0% | 32 | $0.00 | |
| 1160F | 0% | 199 | $0.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 76 | $0.00 |
| 76937 | 0% | 31 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 38 | $0.00 |
| 3077F | 0% | 12 | $0.00 | |
| 3074F | 0% | 1,016 | $0.00 | |
| 3008F | 0% | 1,297 | $0.00 | |
| 1036F | 0% | 883 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 86 | $0.00 |
| 3079F | 0% | 462 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 36 | $0.00 |
| 4010F | 0% | 15 | $0.00 | |
| 1034F | 0% | 132 | $0.00 | |
| 3075F | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUNTZ, ADAM (CFO)
Parent organizationORRVILLE HOSPITAL FOUNDATION
| Provider | Location | Paid |
|---|---|---|
| Aultman Now Urgent Care, LLC | North Canton, OH | $2.49M |
| North Central Medical Resources, INC | Canton, OH | $2.47M |
| Aultman Hospital | Canton, OH | $470K |
| Orrville Hospital Foundation | Carrollton, OH | $418K |
| Orrville Hospital Foundation | Dover, OH | $185K |
| Aultman Cancer Care LLC | Canton, OH | $158K |
| Orrville Hospital Foundation | Bolivar, OH | $91K |
| North Central Medical Resources, INC | Alliance, OH | $62K |
| Orrville Hospital Foundation | Dover, OH | $13K |
| Orrville Hospital Foundation | Alliance, OH | $11K |
| North Central Medical Resources, INC. | North Canton, OH | $11K |
| Orrville Hospital Foundation | Doylestown, OH | $5K |
| North Central Medical Resources, INC | Orrville, OH | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.